记者 周楠 通讯员 王笛 在企业位于普陀桃浦的研发基地，记者看到这款手部外骨骼设备通体采用软钢结构，尺寸与普通手 套相近，穿戴弹力辅助装置后即可使用。其核心的神经接口驱动模块由企业自主研发，通过固定在小臂 上的采集装置，可精准捕捉使用者的肌电信号。 "该模块可同时采集屈肌与伸肌部位的信号，检测患者运动意图。通过分析信号的精细变化，判断 患者是想伸手还是握拳，进而实现对不同形状、大小物体的拾取与释放。"企业研发总监汪洋解释。 作为国内首个注册神经接口驱动"手功能辅助系统"，该设备可让患者大脑重新掌控患侧手部运动， 为万千脑卒中手功能障碍患者带来功能重建的新曙光。"临床试验结果显示，佩戴外骨骼后，患者运动 功能评分的提升均值达到未佩戴时的69.29%，实现从无法抓取物体到自主完成抓取动作的跨越。"汪洋 说。 1月7日，总部位于普陀区的上海海每康智能医疗科技有限公司成功获得国内第一张神经接口驱动的 手功能辅助系统医疗器械注册证。这意味着，用于脑卒中等疾病康复辅助治疗的手部外骨骼设备将加速 走入患者生活。 据悉，获得医疗器械注册证，意味着该产品已完成技术研发、临床验证、标准合规全流程，正式具 备上市资格。企业总经理助 ...

Industry Research - The solid-state battery industry is entering a new phase, with consensus on mass production validation by 2026-2027, driven by multiple catalysts. The divergence lies in the process routes and pilot verification, as well as the ability to achieve a commercial closed loop by 2030. The assessment of technology and manufacturing maturity indicates that solid-state technology will progress from stages 5-6 to 7-8. The mid-term focus is on equipment and key materials, while the long-term shift will be towards leading solid-state companies and material companies with core patents [4]. PCB Equipment - The demand for AI computing power is driving a wave of capital expenditure in the PCB industry, with domestic PCB equipment manufacturers expected to see sustained order growth. The industry outlook remains positive, with NVIDIA's Rubin architecture potentially reshaping the demand and landscape for drilling equipment and needles [6]. Company Analysis - Meilan De (688273.SH) has been a leader in the domestic pelvic floor dysfunction (PFD) market for over a decade, focusing on pelvic and obstetric rehabilitation equipment. The company is expanding into reproductive anti-aging, sports rehabilitation, light medical beauty, and brain-machine interface fields, rapidly building a product matrix for women's health throughout their life cycle through self-research and acquisitions. The company utilizes various energy source technologies, including ultrasound, laser, electrophysiology, electrical stimulation, magnetic stimulation, and high-frequency, continuously leading industry development [6]. - Shuanglin Co. (300100.SZ) has been deeply involved in the automotive parts industry for 40 years, gradually forming industrial advantages through internal improvements and external acquisitions. The equipment and screw rod business are expected to become new growth drivers for the company. The outlook for the second half of 2026 is positive, with expectations for gradual increases in robot deployment and trends towards domestic screw rod replacement. Shuanglin possesses unique advantages in screw rod grinding equipment and processes, making it a rare player in the domestic screw rod field [8].

Core Viewpoint - The company has approved a change in the purpose of repurchased shares, shifting from employee stock ownership plans to cancellation and reduction of registered capital [1]. Group 1: Share Repurchase and Capital Reduction - The company’s board and shareholders have agreed to adjust the use of 1,459,586 repurchased shares from "for employee stock ownership plans or equity incentives" to "for cancellation and corresponding reduction of registered capital" [1]. - The company has completed the necessary registration changes and obtained a new business license reflecting the updated registered capital of 316,492,922 yuan [1]. Group 2: Company Information - The company is named Qingdao Haier Biomedical Co., Ltd., with a unified social credit code of 91370211780374731M, established on October 28, 2005 [1]. - The company operates in various sectors including medical device technology research and development, production, sales, and after-sales services, as well as other related fields [1].

——编 者 定标准，规范医疗服务 本报记者 申少铁 国家药品监督管理局发布的《采用脑机接口技术的医疗器械 术语》医疗器械行业标准，于1月1日正式 实施。这是我国首个脑机接口医疗器械标准。为什么要制定这个标准？其主要内容是什么？对脑机接口 技术发展有什么意义？为了回答读者关心的问题，记者采访了国家药监局器械注册司副司长袁鹏。 问：该标准对采用脑机接口技术的医疗器械作出了什么定义？ 图①：中国科学院脑科学与智能技术卓越创新中心微纳电子加工平台，工作人员在加工侵入式脑机接口 柔性电极。 图②：北京天坛医院脑机接口门诊，医生在为患者进行脑电信号检测。 北京天坛医院供图 图③：瘫痪患者通过侵入式脑机接口系统，用意念控制机器狗。 图①③均为中国科学院脑科学与智能 技术卓越创新中心提供 "十五五"规划建议提出，"推动量子科技、生物制造、氢能和核聚变能、脑机接口、具身智能、第六代 移动通信等成为新的经济增长点。" 1月1日，我国首个脑机接口医疗器械标准正式实施。从患者用意念操控电脑到指挥机械臂、机器狗，从 实验室的前沿科技到门诊里的问询评估……当下，脑机接口技术飞速发展，正加快接入现实生活，相关 政策、标准的发布，为"接入" ...

"十五五"规划建议提出，"推动量子科技、生物制造、氢能和核聚变能、脑机接口、具身智能、第六代 移动通信等成为新的经济增长点。" 1月1日，我国首个脑机接口医疗器械标准正式实施。从患者用意念操控电脑到指挥机械臂、机器狗，从 实验室的前沿科技到门诊里的问询评估……当下，脑机接口技术飞速发展，正加快接入现实生活，相关 政策、标准的发布，为"接入"现实描画了更加清晰的路径。本期"瞰前沿"关注脑机接口行业新标准、新 动态，探寻技术与现实的"接口"。 ——编者 定标准，规范医疗服务 该标准有利于为脑机接口这一新兴领域建立统一的"语言体系"。首先，统一术语可打通不同学科间的对 话渠道，为跨领域科研协作、产品研发、临床推广等奠定坚实基础，也为医疗器械监管提供清晰、一致 的技术依据，有助于提升产品研发和注册申报效率；其次，通过为脑机接口医疗器械确立准入门槛与技 术标杆，有效引领市场从概念炒作回归价值竞争，优化创新产业发展生态；第三，它为后续"性能测试 方法""人工智能算法数据质量"等一系列标准的建立奠定了基础，标志着覆盖脑机接口医疗器械全生命 周期的标准体系开始全面构建。 问：采用脑机接口技术的医疗器械有什么潜力？ 国家药品监 ...

赛诺医疗科学技术股份有限公司关于公司产品在海外获得注册证的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于2023年向哈萨克斯坦共和国卫生部 （Ministry of Health of the Republic of Kazakhstan,以下简称MoH）递交了公司HT Supreme?药物洗脱支架 系统、SC HONKYTONKTM 冠脉球囊扩张导管和NC ROCKSTARTM非顺应性球囊扩张导管的注册申报 资料。公司于近日收到通知，HT Supreme? 药物洗脱支架系统 、SC HONKYTONKTM 冠脉球囊扩张导 管及NC ROCKSTARTM 非顺应性球囊扩张导管及的注册申报资料获得MoH的批准。现将相关情况公告 如下： 一、注册证内容 1、HT Supreme?药物洗脱支架系统 证券代码：688108 证券简称：赛诺医疗 公告编号：2026-001 证书编号：KZ77VBP00029837 证书编号：KZ66VBP0002984 ...

证券代码：688139 证券简称：海尔生物 公告编号：2026-003 青岛海尔生物医疗股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 青岛海尔生物医疗股份有限公司（以下简称"公司"）于2025年10月30日、2025年11月17日分别召开了第 三届董事会第八次会议和2025年第一次临时股东大会，分别审议通过了《关于变更部分回购股份用途并 注销暨减少注册资本的议案》，同意公司将存放于回购专用账户中的1,459,586股已回购股份的用途进行 调整，由"用于员工持股计划或股权激励"调整为"用于注销并相应减少注册资本"，同时按照相关规定办 理注销手续，具体内容详见公司分别于2025年10月31日和2025年11月18日在上海证券交易所网站 （www.sse.com.cn）披露的《青岛海尔生物医疗股份有限公司关于变更部分回购股份用途并注销暨减少 注册资本的公告》（公告编号：2025-049）和《青岛海尔生物医疗股份有限公司2025年第一次临时股东 大会决议公告》（公告编号：2 ...

证券代码：603309 证券简称：维力医疗 公告编号：2026-007 广州维力医疗器械股份有限公司 关于2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 2026年1月9日，公司第五届董事会第十九次会议以6票同意、0票反对、0票弃权的表决结果审议通过了 《关于公司2026年度日常关联交易预计的议案》，关联董事向彬回避表决。鉴于公司2026年度日常关联 交易的预计额度在董事会决策权限内，该议案无需提交股东会审议。 2、独立董事专门会议审议情况 2026年1月9日，公司第五届董事会独立董事专门会议第六次会议以3票同意、0票反对、0票弃权的表决 结果审议通过了《关于公司2026年度日常关联交易预计的议案》，全体独立董事发表意见如下：公司预 计的2026年度日常关联交易属于公司正常生产经营范围内发生的常规业务，符合公司日常生产经营活动 和业务发展的实际需要，定价原则以市场价格为参考协商确定价格，遵循了公平、公正、公开、自愿、 诚信的原则，不存在损害公司及全体股东利益的情况。同意将上述 ...

两融数据显示，该股最新融资余额为4649.19万元，近5日增加680.26万元，增幅为17.14%。（数据宝） 1月9日爱威科技大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 盘折溢价 | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | （%） | | | | 12.00 | 300.36 | 25.03 | -4.50 | 华泰证券股份有限公司天津 东丽开发区二纬路证券营业 | 国联民生证券股份有限公司 北京建材城西路证券营业部 | | | | | | 部 | | （文章来源：证券时报网） 爱威科技1月9日大宗交易平台出现一笔成交，成交量12.00万股，成交金额300.36万元，大宗交易成交价 为25.03元，相对今日收盘价折价4.50%。该笔交易的买方营业部为华泰证券股份有限公司天津东丽开发 区二纬路证券营业部，卖方营业部为国联民生证券股份有限公司北京建材城西路证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为2158.3 ...

Summary of Key Points Core Viewpoint The North Exchange has seen a significant fluctuation in trading volume and value, with new companies entering the market and others undergoing various stages of the IPO process. The overall market activity reflects both challenges and opportunities for investors. Trading Activity - As of January 4, 2026, the North Exchange has 288 listed companies with a total share capital of 39.744 billion shares and a circulating share capital of 25.334 billion shares [2] - For the week of December 29 to December 31, the trading volume was 2.394 billion shares, a decrease of 48.33% from the previous week, while the trading value was 58.316 billion yuan, down 41.65% [3] - The average trading price increased by 12.94% to 24.36 yuan [3] - The North Exchange 50 Index fell by 1.55% to 1440.43 points, with 19 stocks rising and 30 falling [3] New Listings and IPOs - One company, Hengtong Communication Technology Co., Ltd., was listed on December 25, 2025, becoming the 288th company on the North Exchange, with a first-day closing price of 309 yuan, up 277.41% [9] - As of January 4, 2026, there are 167 companies awaiting approval for listing, with 51 accepted, 93 in inquiry, and 11 having passed the listing committee [6] - During the week of December 29 to January 4, four companies received IPO registration approvals, including Tongling Technology and Haiseng Medical [16][22][26][31] Financial Performance of Listed Companies - Hengtong Communication reported revenues of 4.75 billion yuan, 6.13 billion yuan, and 13.15 billion yuan from 2022 to 2024, with net profits of 55.33 million yuan, 64.53 million yuan, and 148 million yuan respectively [13] - Tongling Technology's revenue for the first three quarters of 2025 decreased by 5.47% to 714 million yuan, while net profit increased by 20.87% to 119 million yuan [21] - Haiseng Medical's revenue for the first half of 2025 grew by 22.56% to 156 million yuan, with a net profit increase of 27.11% to 35.49 million yuan [25] Upcoming IPOs and Market Trends - Several companies, including MoSen Tech and Senfeng Laser, have received approval for their IPO applications, indicating a robust pipeline for new listings [47][49] - The market is witnessing a trend of companies focusing on high-tech and innovative sectors, such as automotive components and medical devices, which may attract investor interest [19][24][26]